Entering text into the input field will update the search result below

AGNPF Algernon Pharmaceuticals Inc.
Stock Price & Overview

$0.06-0.0062 (-9.81%)11:02 AM 12/04/23
OTCQB | $USD | Delayed


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Algernon Pharmaceuticals Inc. logo
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, pancreatic and small cell lung cancer, and acute lung injury in Canada, Australia, and New Zealand. The company’s pipeline includes Ifenprodil, which completed Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in preclinical stage for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which has completed preclinical stage for the treatment of strokes. The company was formerly known as “Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in July 2015. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
  • 601 West Broadway
  • Suite 400
  • Vancouver, BC, V5Z 4C2
  • Canada
Phone Number
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.